Christopher Bunker, Ph.D., M.B.A.

Christopher Bunker, Ph.D., M.B.A. has an extensive work experience in the biopharma industry. Christopher is currently the Vice President of Biopharma Business Development at Alamar Biosciences, Inc., a position they have held since February 2022. Prior to that, they worked at Triplebar as the Senior Director of Biopharma Business Development from October to December 2021.

From 2016 to 2021, Bunker served as the Senior Director of Business Development at Advanced Cell Diagnostics, a Bio-Techne Brand. During their time there, they were responsible for expanding ACD's biomarker development business and developing and managing global biopharma client service relationships. Christopher also built business partnerships with major CLIA CROs to enable CDx strategy and expand revenue channels. Before this role, they were the Vice President of Business Development from 2010 to 2021 and played a crucial role in expanding ACD's client base and increasing the company's valuation trajectory.

Prior to their tenure at Advanced Cell Diagnostics, Bunker worked at Cell Signaling Technology from 2000 to 2010. Christopher held various positions at the company, including Director of Business Development and Drug Discovery Market Specialist. In these roles, they aligned CST's pathway analysis platforms in pharma services businesses, established and built a global pharma service business, and developed customer relations with pharma and biotech companies.

Bunker's career in the biopharma industry began at Genome Therapeutics Corporation, where they worked as a Senior Scientist from 1997 to 2000. In that role, they focused on cancer target discovery, identified and implemented technologies to build functional genomics capabilities, and established core cDNA microarray technology.

Overall, Christopher Bunker, Ph.D., M.B.A. has demonstrated a strong track record of success in biopharma business development, client relationship management, and strategic partnerships.

Christopher Bunker, Ph.D., M.B.A. holds a Doctor of Philosophy (Ph.D.) degree in Biological Chemistry & Molecular Pharmacology from Harvard University, which they earned from 1988 to 1995. Christopher continued their education at the University of California, San Francisco from 1995 to 1997, where they completed a postdoctoral fellowship sponsored by the Leukemia Society. During this fellowship, they focused on Molecular Genetics. Later, Christopher pursued a Master of Business Administration (M.B.A) degree in Business from the Questrom School of Business at Boston University from 2008 to 2010. In 1983, they completed their Bachelor of Science (B.Sc.) degree in Biochemistry at McGill University, where they studied from 1983 to 1987.